Axial Spondyloarthritis (axSpA) Market Spotlight, 2020: Key Marketed & Pipeline Drugs, Clinical Trials, Patent Information, 10-Year Disease Prevalence Forecast, Deals, Drug-Specific Revenue Forecasts - ResearchAndMarkets.com

DUBLIN--()--The "Market Spotlight: Axial Spondyloarthritis (axSpA) 2020" report has been added to ResearchAndMarkets.com's offering.

This Market Spotlight report covers the Axial Spondyloarthritis (axSpA) market, comprising key marketed and pipeline drugs, recent events and analyst opinion, clinical trials, upcoming and regulatory events, probability of success, patent information, a 10-year disease prevalence forecast, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts.

  • The report estimates that in 2018, there were 5.9 million prevalent cases of ankylosing spondylitis in adults aged 20 years and older worldwide, and forecasts that number to increase to 6.4 million prevalent cases by 2027.
  • The approved drugs in the axial spondyloarthritis (axSpA) space target tumor necrosis factor-alpha, prostaglandin E receptor 1, prostaglandin E receptor 2, and IL-17. These are commonly administered via the subcutaneous route, with the remainder being intravenous and oral formulations.
  • The majority of industry-sponsored drugs in active clinical development for axSpA are in Phase III. Therapies in development for axSpA focus on targets such as JAK/STAT, IL-17, tumor necrosis factor-alpha, and granulocytemacrophage colony-stimulating factor (GM-CSF). These drugs are administered via the oral, intravenous, subcutaneous, and topical routes.
  • High-impact upcoming events in the axSpA space comprise topline Phase III trial results, expected PDUFA dates, a CHMP opinion, a supplemental CHMP opinion, and supplemental CHMP filing results.
  • The overall likelihood of approval of a Phase I arthritis asset is 9.9%, and the average probability a drug advances from Phase III is 80%. Drugs, on average, take 8.8 years from Phase I to approval, compared to 9.0 years in the overall autoimmune/immunology space.
  • There have been 10 licensing and asset acquisition deals involving axSpA drugs during 2015-20. The $132m agreement signed in 2018 between Grunenthal and AstraZeneca for the acquisition of European rights to Nexium and global (ex-US and Japan) rights to Vimovo was the only deal with a publicly released value.
  • The distribution of clinical trials across Phase I-IV indicates that the majority of trials for axSpA have been in the late phases of development, with 82% of trials in Phase III-IV, and only 18% in Phase I-II.
  • Germany has a substantial lead in the number of axSpA clinical trials globally, while South Korea has the top spot in Asia. Clinical trial activity in the axSpA space is dominated by completed trials. AbbVie has the highest number of completed clinical trials for axSpA, with 27 trials.
  • Pfizer leads industry sponsors with the highest overall number of clinical trials for axSpA, followed by AbbVie

Key Topics Covered

1. OVERVIEW

2. KEY TAKEAWAYS

3. DISEASE BACKGROUND

  • Definition
  • Patient segmentation
  • Symptoms
  • Risk factors
  • Diagnosis

4. TREATMENT

5. NSAIDs

6. DMARDs

  • Steroids
  • Surgery

7. EPIDEMIOLOGY

  • Epidemiology of axial spondyloarthritis

8. MARKETED DRUGS

9. PIPELINE DRUGS

10. RECENT EVENTS AND ANALYST OPINION

  • Cosentyx for Axial Spondyloarthritis (November 12, 2019)
  • Rinvoq for Axial Spondyloarthritis (November 12, 2019)
  • Taltz for Axial Spondyloarthritis (November 12, 2019)
  • Inflectra for Axial Spondyloarthritis (September 19, 2019)
  • Cosentyx for Axial Spondyloarthritis (September 17, 2019)
  • Taltz for Axial Spondyloarthritis (April 22, 2019)
  • SensoReady Injector Pen for Axial Spondyloarthritis (April 9, 2019)
  • Taltz for Axial Spondyloarthritis (October 22, 2018)
  • Taltz for Axial Spondyloarthritis (October 20, 2018)
  • Filgotinib for Axial Spondyloarthritis (September 6, 2018)

11. KEY UPCOMING EVENTS

12. KEY REGULATORY EVENTS

  • Amgen Gets US Infliximab Nod
  • With Launch Years Away, FDA Touts Approval Of Fifth Humira Biosimilar
  • Bio-Thera Solutions Has China's First Adalimumab Biosimilar
  • Lilly's Taltz Approved For AS As New Guidelines Keep TNF Inhibitors In Front Line
  • Samsung Bioepis Gets US Adalimumab Nod
  • Eticovo Becomes Second Approved Enbrel Biosimilar After Under-The-Radar Review
  • Cimzia Lands New Indication For Unmet Need

13. PROBABILITY OF SUCCESS

14. LICENSING AND ASSET ACQUISITION DEALS

15. PARENT PATENTS

16. REVENUE OPPORTUNITY

17. CLINICAL TRIAL LANDSCAPE 3 PROBABILITY OF SUCCESS

18. LICENSING AND ASSET ACQUISITION DEALS

19. PARENT PATENTS

20. REVENUE OPPORTUNITY

21. CLINICAL TRIAL LANDSCAPE

  • Sponsors by status
  • Sponsors by phase
  • Recent events

22. BIBLIOGRAPHY

23. APPENDIX

Companies Mentioned

  • Amgen
  • Bio-Thera Solutions
  • Samsung

For more information about this report visit https://www.researchandmarkets.com/r/4fakj3.

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900